This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, S L
Right arrow Articles by Seo, S M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, S L
Right arrow Articles by Seo, S M

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 December; 38(12): 2702-2709

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

S L Kang, M J Rybak, B J McGrath, G W Kaatz and S M Seo

Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center, MI 48201.

ABSTRACT

The pharmacodynamic properties of levofloxacin (an optically active isomer of ofloxacin), ofloxacin, and ciprofloxacin, alone and in combination with rifampin, were evaluated over 24 to 48 h against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA 1199 and MRSA 494, respectively) in an in vitro infection model. The incidence of the emergence of resistance among the test strains was also determined. The fluoroquinolones were administered to simulate dosage regimens of 200 mg, 400 mg given intravenously (i.v.) every 12 h (q12h), and 400 and 800 mg given i.v. q24h. Rifampin was dosed at 600 mg i.v. q24h. Although the MICs and MBCs of the quinolones were similar (< or = 0.49 microgram/ml), levofloxacin was the most potent agent in time-kill studies on the basis of the time required to achieve a 99.9% reduction in the number of log10 CFU per milliliter (e.g., with the regimen of levofloxacin [400 mg q24h, 6.5 h] versus ofloxacin [12.5 h], P < 0.024, and levofloxacin versus ciprofloxacin [6.5 versus 9.0 h], P < 0.0017) against MSSA 1199. The killing activity of levofloxacin was similar to that of ofloxacin against MRSA 494 (time to achieve a 99.9% reduction in the number of log10 CFU per milliliter, 11.1 versus 13.8 h, respectively). Levofloxacin and ofloxacin dosed once daily demonstrated greater bactericidal activity than when they were dosed twice daily against MSSA 1199. Resistance to levofloxacin or ofloxacin was not observed with any dosage regimen. Furthermore, resistance to ofloxacin was not detected when the half-life was reduced from 6 to 3 h. Regrowth and stable resistance (65-fold increase in the MIC for MSSA 1199; 16-fold increase in the MIC for MRSA 494) were noted within 24 h of exposure to ciprofloxacin at 200 mg q12h. Combination therapy with rifampin prevented the emergence of resistance to ciprofloxacin. Neither DNA gyrase alteration nor an energy-dependent efflux process mediated by the norA gene appeared to be responsible for the resistance observed. Our data suggest that with levofloxacin there is a more rapid onset of bactericidal activity than with ofloxacin or ciprofloxacin against MSSA 1199 and that the activity of levofloxacin is similar to that of ofloxacin but better than that of ciprofloxacin against MRSA 494. Resistance was noted only after exposure to the low dose of ciprofloxacin. Resistance to ofloxacin did not develop even when the pharmacokinetics of the drug were set to equal those of ciprofloxacin, suggesting that ofloxacin differs from ciprofloxacin irrespective of time of exposure. The resistance to ciprofloxacin that developed in our vitro model may be mediated by the cfx-ofx locus, which has been shown to be associated with low-level fluoroquinolone resistance. Overall, levofloxacin demonstrated potent bactericidal activity against S. aureus, without the emergence of resistance in our infection model. Quinolones dosed once daily were more effective than equivalent dosages administered twice daily. The addition of rifampin was not synergistic but prevented the emergence of ciprofloxacin resistance.

Antimicrob Agents Chemother. 1994 December; 38(12): 2702-2709




This article has been cited by other articles:

  • Leonard, S. N., Kaatz, G. W., Rucker, L. R., Rybak, M. J. (2008). Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 62: 1305-1310 [Abstract] [Full Text]  
  • Murillo, O., Pachon, M. E., Euba, G., Verdaguer, R., Tubau, F., Cabellos, C., Cabo, J., Gudiol, F., Ariza, J. (2008). Antagonistic Effect of Rifampin on the Efficacy of High-Dose Levofloxacin in Staphylococcal Experimental Foreign-Body Infection. Antimicrob. Agents Chemother. 52: 3681-3686 [Abstract] [Full Text]  
  • Perlroth, J., Kuo, M., Tan, J., Bayer, A. S., Miller, L. G. (2008). Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature. Arch Intern Med 168: 805-819 [Abstract] [Full Text]  
  • Campion, J. J., Chung, P., McNamara, P. J., Titlow, W. B., Evans, M. E. (2005). Pharmacodynamic Modeling of the Evolution of Levofloxacin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 2189-2199 [Abstract] [Full Text]  
  • Campion, J. J., McNamara, P. J., Evans, M. E. (2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother. 48: 4733-4744 [Abstract] [Full Text]  
  • Welling, M. M., Lupetti, A., Balter, H. S., Lanzzeri, S., Souto, B., Rey, A. M., Savio, E. O., Paulusma-Annema, A., Pauwels, E. K.J., Nibbering, P. H. (2001). 99mTc-Labeled Antimicrobial Peptides for Detection of Bacterial and Candida albicans Infections. JNM 42: 788-794 [Abstract] [Full Text]  
  • Firsov, A. A., Lubenko, I. Yu., Vostrov, S. N., Kononenko, O. V., Zinner, S. H., Portnoy, Y. A. (2000). Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother 46: 725-732 [Abstract] [Full Text]  
  • MacGowan, A., Rogers, C., Bowker, K. (2000). The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. J Antimicrob Chemother 46: 163-170 [Full Text]  
  • MacGowan, A., Rogers, C., Holt, H. A., Wootton, M., Bowker, K. (2000). Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. J Antimicrob Chemother 46: 73-78 [Abstract] [Full Text]  
  • Bowker, K. E., Wootton, M., Rogers, C. A., Lewis, R., Holt, H. A., MacGowan, A. P. (1999). Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. J Antimicrob Chemother 44: 661-667 [Abstract] [Full Text]  
  • Chambers, H. F., Xiang, Q., Liu, , Chow, L. L., Hackbarth, C. (1999). Efficacy of Levofloxacin for Experimental Aortic-Valve Endocarditis in Rabbits Infected with Viridans Group Streptococcus or Staphylococcus aureus. Antimicrob. Agents Chemother. 43: 2742-2746 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Kaatz, G. W., Rybak, M. J. (1999). The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model. J Antimicrob Chemother 44: 343-349 [Abstract] [Full Text]  
  • Amorena, B., Gracia, E., Monzon, M., Leiva, J., Oteiza, C., Perez, M., Alabart, J.-L., Hernandez-Yago, J. (1999). Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother 44: 43-55 [Abstract] [Full Text]  
  • Firsov, A. A., Vasilov, R. G., Vostrov, S. N., Kononenko, O. V., Lubenko, I. Yu., Zinner, S. H. (1999). Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother 43: 483-490 [Abstract] [Full Text]  
  • Sulavik, M. C., Barg, N. L. (1998). Examination of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Mutants with Low-Level Fluoroquinolone Resistance. Antimicrob. Agents Chemother. 42: 3317-3319 [Abstract] [Full Text]  
  • Firsov, A. A., Vostrov, S. N., Shevchenko, A. A., Portnoy, Y. A., Zinner, S. H. (1998). A New Approach to In Vitro Comparisons of Antibiotics in Dynamic Models: Equivalent Area under the Curve/MIC Breakpoints and Equiefficient Doses of Trovafloxacin and Ciprofloxacin against Bacteria of Similar Susceptibilities. Antimicrob. Agents Chemother. 42: 2841-2847 [Abstract] [Full Text]  
  • Evans, M. E., Titlow, W. B. (1998). Selection of Fluoroquinolone-Resistant Methicillin-Resistant Staphylococcus aureus with Ciprofloxacin and Trovafloxacin. Antimicrob. Agents Chemother. 42: 727-727 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»